Priya Dave1, Ghizlane Yaakoubi2, Justin Loloi1, Niraj Shenoy3,*, Ahmed Aboumohamed1,*
Canadian Journal of Urology, Vol.32, No.3, pp. 167-172, 2025, DOI:10.32604/cju.2025.063279
- 27 June 2025
Abstract Background: Primary renal myoepithelial carcinoma is an exceptionally rare malignancy with limited data on optimal treatment, particularly in metastatic settings. Case Description: In 2020, Shenoy reported a dramatic response in a case of metastatic myoepithelial carcinoma with Ewing sarcoma breakpoint region 1-POU class 5 homeobox 1 (EWSR1-POU5F1) fusion arising from the left kidney using the Ewing Sarcoma vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (VDC/IE) chemotherapy regimen. Ten months post-treatment, the patient showed ~90% reduced disease burden on imaging. Subsequent treatment included consolidation vincristine, cyclophosphamide/ifosfamide, etoposide (VC/IE) chemotherapy, surgical resection of the remnant tumor, and follow-up imaging. Conclusion: The More >